Alexandria told investors the life-science market was strong. Occupancy was solid. Leasing spreads were healthy. And its Long Island City campus was supposed to be a growth engine.

But the truth was very different.

By late October 2025, executives revealed that the LIC submarket suffered a setback and never recovered after Amazon abandoned its planned HQ in 2019. The property wasn’t a life-science hub at all. On October 28, 2025, the Company revealed a devastating impairment charge of about $320 million, with more than $200 million tied to that single LIC asset.

Guidance for 2025 was cut. Occupancy was lower than they had claimed. Leasing had slowed.

Investors were blindsided. The stock plunged about 19% in one day. Now, more investors are joining the lawsuit.

Sprouts Farmers Market spent 2025 telling investors a simple story. Their customers were loyal. Their sales were strong. And even with a cautious consumer, Sprouts said it would thrive.

But the truth? Things were already starting to crack. On June 4, executives insisted demand wasn’t slowing. On July 13, they raised guidance, promising 7 to 9% comparable growth for the year. They told investors their shoppers were resilient and that any consumer weakness would actually help them.

Then October 29 hit. Sprouts revealed sales growth had slipped to under 6%. Fourth-quarter expectations collapsed to nearly 0. Full-year projections were slashed just months after being raised. And the stock? It plunged about 26% in a single day.

Investors were stunned. Confidence vanished. Now, more shareholders are joining the lawsuit.

StubHub told investors the story everyone wanted to hear. A global marketplace. Huge demand. Strong cash flow. A fresh IPO in September. It all sounded like the perfect ticket to growth.

But the truth showed up fast.

Just weeks later, on November 13, 2025, StubHub revealed free cash flow had flipped to negative $4.6 million. That was a drop of about 140% from the year before. The company also admitted operating cash collapsed nearly 70%. And executives blamed it on the timing of payments to vendors, something the lawsuit says they should have disclosed before the IPO.

Investors were stunned. The stock fell about 20% in a single day and kept sliding, losing more than half its value.

Now, more investors are joining the lawsuit.

Jayud Global promised investors a fast-growing logistics empire. A lean operation. Big global reach. A company on the rise. But behind the scenes, something very different was happening.

From late 2024 into early 2025, Jayud’s stock started soaring for no clear reason. Then, on April 1, 2025, it suddenly spiked to nearly $8. Overnight. No major news. No big win. Just hype.

According to the complaint, that “hype” came from a coordinated online promotion scheme. Fake analysts in chat rooms. Wild price targets. Impersonators flooding WhatsApp and YouTube. Investors were told Jayud was the next breakout. Meanwhile, insiders and affiliates were allegedly dumping shares as the buying frenzy grew.

Then came the crash. After hours on April 1, the stock collapsed about 95%. By the next morning, investors were stunned. Confidence evaporated.

Now, more investors are joining the lawsuit.

Freeport-McMoran kept telling investors everything at its giant Indonesia copper mine was safe. Operations strong. Risk under control. A bright future ahead. But the truth was far darker.

Starting in February 2022, executives repeated the same message year after year. They said they had rigorous safety systems. They said the risks at the Grasberg Block Cave were managed. Investors trusted them.

Then came September 8, 2025. A massive rush of wet material tore through the mine. 7 workers were trapped. Days later, Freeport revealed 2 were found dead, and 5 were still missing.

Production halted. Guidance cut. By September 24, the stock had fallen about 17% in a single day. Confidence collapsed.

Experts later said the danger was known and should have been anticipated.

Now, more investors are joining the lawsuit.

Stride told families it was building one of the nation’s most successful online education platforms. Big vision. Big growth. A future full of opportunity.

But behind the scenes, the truth was unraveling.

Starting in October 2024, executives kept promising strong demand and rising enrollments. Then came January. Then April. Then August. Each quarter, Stride painted the same picture of momentum and record interest.

The lawsuit says the real story was very different. Stride was inflating student rolls with ghost enrollments, stretching teachers past legal limits, ignoring compliance rules, and losing families who saw the cracks.

On September 14, 2025, a school district publicly accused Stride of fraud. The stock fell about 12% overnight.

Then, on October 28, Stride admitted thousands of students had walked away after poor experiences. The stock crashed over 50%.

Shareholders were stunned. Confidence collapsed.

Now, more investors are joining the lawsuit.

They said the merger would change everything. A powerhouse. Coast-to-coast brands. Growth for years. That was the pitch.

But behind the scenes, things were falling apart.

In June 2024, Primo Water and BlueTriton announced their big all-stock deal. Executives promised “flawless integration” and hundreds of millions in synergies. Then, in February and May of 2025, they repeated that message, telling investors everything was on track.

It wasn’t. Through the summer, warehouses shut too fast, systems broke, and customers couldn’t get product. On August 7, 2025, the first cracks showed when the company quietly admitted service disruptions. Shares slipped about 9%.

Then November 6 hit. Primo slashed its guidance, replaced its CEO, and finally admitted the merger was “more complicated” than they ever let on. The stock collapsed about 36% in 2 days, wiping out billions in value.

Now, more investors are joining the lawsuit.

Firefly Aerospace just got hit with a major securities class-action lawsuit over its August 2025 IPO.

Investors claim the company and execs overstated demand for its Spacecraft Solutions business and hyped the Alpha rocket as "flight proven" and ready for commercial launches — despite four failures in 6 tests and an FAA grounding after April's explosion.

The reality? On September 22, a Q2 earnings report showed a loss of $80 million, with revenue down 26% YoY. The stock dropped 15%.

Days later on September 29, the first stage of Firefly’s Alpha Flight 7 failed right after the CEO said launch was imminent. The stock took another 21% plunge.

The lawsuit says these risks were hidden, inflating the IPO price and hurting buyers. If you bought FLY shares between August 7th and September 29th of 2025, you were harmed. Join now.

Telix promised a future full of growth. New cancer drugs. A global rollout. A rock-solid supply chain. Investors were excited. Everything looked set for a major leap.

But the story behind the scenes was very different.

In February 2025, Telix told investors its prostate cancer program was thriving and its manufacturing partners were ready to scale. In July, that confidence cracked. The company revealed the SEC had issued a subpoena over its prostate cancer disclosures. Shares dropped about 15%.

Then came August 2025. The FDA sent Telix a harsh letter, citing manufacturing problems and deficiencies at two of Telix’s partners. The stock fell another 16% in a single day. Investors were stunned. Trust evaporated.

Now, more investors are joining the lawsuit.

Molina Healthcare promised steady growth and solid earnings. Executives said medical costs were under control and 2025 was on track. Investors expected stability.

But behind the curtain, something very different was happening.

In February 2025, the company reaffirmed strong guidance. In April, they repeated the same message. Then July hit. On July 7, Molina admitted medical costs were rising fast and cut earnings guidance by about 10%. The stock slipped.

Just 16 days later, on July 23, the truth landed harder. Molina slashed guidance again, this time to no less than $19 a share. They blamed accelerating medical costs and higher use of behavioral health, pharmacy, and inpatient care. The stock collapsed nearly 17% in a single day.

Investors were stunned. Confidence evaporated.

Now, more shareholders are joining the lawsuit.

Inspire said its new sleep apnea device, Inspire V, was the future. Executives promised strong demand, smooth rollout, and a “simple” launch.

However, behind the scenes, providers were stuck with old inventory, key systems weren’t ready, and many clinics couldn’t even bill insurers. Demand was weak, and Inspire hadn’t finished basic training or setup.

Then on August 4, 2025, the truth came out. Inspire slashed its profit forecast by more than 80%, admitting its launch had collapsed. The stock plunged about 32% in a single day — wiping out more than a billion dollars in value.

Investors were stunned. Confidence gone. Now, more shareholders are joining the lawsuit.

Marex promised strength. Solid liquidity, fast growth, and reliable profits. Investors believed it. But cracks started to show.

In August 2024, Marex claimed billions in cash and said it could handle any market storm. By fall, executives praised “excess liquidity” from structured notes — money that wasn’t true earnings. Then in March 2025, revenue dropped sharply. The company blamed low volatility, but the truth was deeper.

According to the complaint, Marex used debt and internal transfers to pad its balance sheet and mask weak cash flow. What looked like stability was smoke and mirrors.

Investors were blindsided. Confidence collapsed. The stock tumbled.

Now, more investors are joining the lawsuit.

CarMax promised investors smooth roads ahead. The CEO said the company was gaining market share, driving double-digit growth, and predicting for “years to come” of strong results.

But under the hood, that success was built on a temporary rush — buyers scrambling to beat rumored car tariffs. Executives knew those numbers wouldn’t last.

By September 2025, the truth arrived. CarMax reported falling sales, shrinking profits, and called the quarter “challenging.” The stock crashed about 20% in one day and kept sliding. Investors were blindsided — the “growth story” they’d been sold was just a short-term boost.

Confidence evaporated. Shares sank. Investors are now speeding to join the lawsuit.

Synopsys told investors its AI-powered chip business was the future. Revenue was rising. Growth looked unstoppable.

But behind the optimism, its most profitable segment — Design IP — was starting to crack. The company’s shift toward AI customers meant expensive custom work that drained margins and slowed deliveries. Despite these facts, executives kept bleating upbeat forecasts.

Then in September 2025, the truth hit. Synopsys admitted its IP business “underperformed,” revenue missed guidance, and profit fell over 40%. The stock collapsed about 36% in a single day.

Investors were blindsided. Confidence gone. Now, more shareholders are joining the lawsuit.

WPP told investors 2025 would be a year of balance and cautious growth. Executives said new business wins would ramp up, offsetting client losses, and that its media arm—now called WPP Media—was ready to compete and thrive even in a tough economy.

But behind the optimism, the company was struggling. Client spending was slowing. The media division was losing market share and dealing with what executives later admitted was “distraction” from restructuring.

Then came July 9, 2025. WPP slashed its outlook, warning of weaker demand and missed expectations. Revenue would fall up to 5%. Margins would shrink. The CEO announced plans to step down.

The market reacted instantly. Shares plunged about 18% in one day. Analysts called it a “profit warning” and said WPP’s decline looked company-specific, not just macroeconomic.

Now, more investors are joining the lawsuit.

Avantor told investors it was holding strong against the competition.

Executives said its lab business was “stacking up well,” with digital tools and momentum to match. But that confidence? It didn’t last.

By April 2025, Avantor admitted “increased competitive intensity” was eating into sales. Guidance was cut, and its CEO announced he was stepping down.

The stock plunged about 16% in a single day.

Then came August—another miss, another cut. Shares dropped fifteen percent more. And by October, Avantor revealed a $700M-plus loss and a massive goodwill impairment. Margins were crushed, big clients gone, and investors were furious.

Now, more shareholders are joining the lawsuit

DexCom promised a life-saving G7 glucose monitor that was supposed to be the most accurate ever made. Investors believed it. But now, the truth isn’t so sweet.

From mid-2024 through 2025, DexCom told investors the G7 was safe, reliable, and improving every quarter. Behind the scenes, the company secretly changed the G7’s sensor design without FDA approval. This change made readings less accurate, more dangerous, and ultimately deadly.

In March 2025, the FDA warned DexCom that its G6 and G7 devices were “adulterated.” The stock fell about 9%. Later, more documents showed patients were hospitalized and even died after faulty readings. By September, a damning report tied those failures to the unapproved design. DexCom’s stock plunged nearly 12%.

Investors were stunned. Lives were lost. Trust was shattered. Now, more shareholders are joining the lawsuit.

James Hardie promised strength and stability — the “number one fiber cement brand in North America,” with booming demand and growth ahead. But that story started to crack.

In May 2025, executives told investors everything looked “normal,” even denying that distributors were cutting back orders. Behind the scenes, they already knew the truth — demand was fading, and warehouses were filling with unsold product.

Then in August, the company finally admitted sales in its biggest segment had dropped about 12% due to “customer destocking.” Investors were blindsided. The stock collapsed more than 34% in two days, wiping out billions in value.

Confidence shattered. Investors are fighting back, joining a lawsuit against James Hardie for misleading them about its real performance.

MoonLake promised a next generation breakthrough. Smaller nanobody. Better tissue reach. Higher responses. Easy monthly shots. It sounded unstoppable.

Then the story shifted. On March 10, 2024, executives told investors their nanobody could do what old antibodies could not. On November 7, 2024, they said those molecular perks meant higher patient responses. On March 8, 2025, they called nanobodies a leap forward.

On April 29, they touted excellent penetration. On July 8, analysts echoed that it was not just a copy. But on September 28, 2025, Phase three results landed. One trial hit. One missed. And the efficacy looked weak next to the approved rival.The fallout was brutal. By September 29, the stock collapsed about 90%, falling about $56 to around $6. Confidence was gone. Now, more investors are joining the lawsuit.

Baxter sold a promise of safer care and a flagship pump that would power years of growth. Best in class. Seamless launch. Investors believed. Here is what the complaint says really happened. April 1, 2024: FDA clears Baxter’s Novum IQ pump for the U.S. market. Executives call it a landmark and say the rollout is going great.

April 7, 2025: a hospital whistleblower warns the pumps are not safe. April 24: Baxter sends a letter about underinfusion risks. June 6: the FDA flags the issue, class one severity. July 14: Baxter discloses about 79 serious injuries and two deaths tied to the pump, and adds overinfusion and non delivery concerns. July 22: another FDA notice follows.

July 31: Baxter pauses all new Novum sales. The stock falls about 22% in a day. Confidence evaporates.

If you bought shares during this period, you may have been misled. Now, more investors are joining the lawsuit.

aTyr Pharma promised investors a breakthrough. Executives said their drug, efzofitimod, could let lung disease patients taper off steroids entirely — calling it a “paradigm-shifting therapy.”

From January through August 2025, aTyr kept repeating that confidence. The Phase Three trial, they said, was “well-powered,” fully enrolled, and on track for “major catalyst” results.

Then came September 15th. The company revealed the study had failed its primary goal — efzofitimod didn’t significantly reduce steroid use compared to placebo. Analysts slashed price targets from sixteen dollars to as low as one.

The stock collapsed about eighty three percent in one day, falling from just over $6 to nearly $1. Investors were blindsided, trust gone.

Now, more investors are joining the lawsuit.

Fortinet promised record growth. Executives said a massive firewall “refresh cycle” would drive hundreds of millions in new revenue through 2026. They told investors the upgrade wave was “by far the largest ever.”

But the truth? That cycle wasn’t new demand at all — it was mostly outdated firewalls, sold more than a decade ago, making up only a small slice of Fortinet’s business. By summer 2025, the company had already forced through nearly half of the upgrades — leaving little left to boost sales.

When Fortinet finally admitted it was already 50% through the so-called two-year cycle, the illusion collapsed. The stock fell more than 22% overnight. Investors were blindsided — and now, more of them are joining the lawsuit.

RCI Hospitality told investors it was running clean clubs and clean books. Turns out, that wasn’t true.

From 2021 through 2024, executives certified spotless financials and claimed tight internal controls. But behind the scenes, RCI’s CEO and CFO were running a multi-year tax fraud—bribing a New York state auditor with lavish trips and cash to dodge over eight million dollars in taxes.

Then, in September 2025, the New York Attorney General unsealed a 79 count indictment. The truth was out—RCI’s top brass were accused of conspiracy, bribery, and criminal tax fraud.

Investors were stunned. The stock plunged about 26% in two days. Confidence gone.

Now, more shareholders are joining the lawsuit.

KBR told investors everything was going smoothly. The company said its HomeSafe program — a joint venture with the U.S. military — was “ramping up,” customer satisfaction was soaring, and revenue would grow through the rest of 2025.

But that wasn’t the truth. Behind the scenes, the Department of Defense had serious concerns about HomeSafe’s performance. KBR knew the partnership was in trouble — even as executives reassured investors everything was fine.

Then, on June 19th, the bomb dropped: TRANSCOM terminated the entire contract. KBR’s stock plunged about 10% in just two days. Investors were blindsided.

Now, more shareholders are joining the lawsuit.

Levi & Korsinsky recently prevailed in a securities fraud appeal at the Second Circuit of Appeals in the matter of Sherman v. Abengoa, S.A. (2d Cir. 2025).

In Abengoa, investors who purchased Abengoa’s American Depository Shares alleged that the Spanish energy and construction company falsified its financial statements to conceal a severe liquidity crisis that led to its 2016 bankruptcy. Plaintiffs alleged that Abengoa’s 2013 SEC registration statement misrepresented that it used the “percentage-of-completion” accounting method accurately, when in fact executives inflated profits, fabricated costs, and shifted expenses between projects to overstate revenue and hide losses. The district court dismissed the claims as untimely and inadequately pleaded, but the Second Circuit reversed in part, holding that the Securities Act claims were timely and plausibly alleged based on detailed insider accounts and corroborating Spanish criminal proceedings. The appellate court reinstated the Securities Act and Exchange Act claims against Abengoa, as well as Securities Act claims against an Abengoa executive and its underwriters.

This decision is significant for a number of reasons, one of which is that the Second Circuit panel held that Plaintiffs had adequately pleaded their claims that Abengoa “orchestrated a fraudulent scheme”; Abengoa was, at the time a multinational corporation and one of Spain’s largest companies, and the case involved a large investigation conducted by Levi & Korsinsky and co-counsel uncovering and piecing together legal proceedings and reports in diverse jurisdictions, the findings of which the Second Circuit held could be relied upon as “detailed, independently corroborated, and the product of an independent investigation.” Perhaps more importantly, the decision clarifies Second Circuit precedent on materiality and pleading standards in securities fraud cases, affirming that investors may rely on detailed factual allegations drawn from credible external investigations and foreign proceedings. The ruling strengthens investor protections by reaffirming that multinational corporations are accountable for false or misleading disclosures in U.S. markets, regardless of where their misconduct originates. It represents a strong statement of law ensuring that global companies engaging in deceptive accounting and reporting practices can be held responsible under U.S. securities laws. Levi & Korsinsky remains committed to fighting for investors harmed by fraud, misrepresentation, and corporate misconduct, wherever that conduct occurs.

Savant v. iRobot Corporation, et al., Case No. 1:25-cv-05563 (S.D.N.Y.) is a securities fraud class action pending before the United States District Court for the Southern District of New York. The complaint, filed in July 2025, alleges that iRobot Corporation and certain of its executives violated federal securities laws by making false and misleading statements about the company’s business, operations, and prospects. According to the allegations, iRobot overstated the extent to which its operational restructuring plan would stabilize the company following the termination of its planned acquisition by Amazon.com, Inc., leading to substantial doubt about its ability to continue as a going concern, inflating its stock price and causing losses to investors who purchased securities during the relevant period.

On October 3, 2025, the Honorable Gary Stein issued an Order appointing Rita Lazaro, Vinayak Savant, and Sergei Daniel as Co-Lead Plaintiffs in the case. The Court also approved the Co-Lead Plaintiffs’ selection of Pomerantz LLP and Levi & Korsinsky, LLP as Co-Lead Counsel.

A copy of the Court's Order can be found here. 

Replimune said everything was good to go with its FDA application for a cancer drug. The data looked great. The FDA was going to approve it. Everything was terrific. Only… none of that was true. After the FDA knocked back the drug application, the stock dropped an eye-popping 77%. Now, investors are suing.

In November 2024, Replimune announced its Biologics License Application for its cancer drug, R-P1. Executives bragged about its Breakthrough Therapy status and said the data was strong. They doubled down in February 2025, boasting again about great results — and that the FDA had accepted the application for priority review.

But here’s what they didn’t say: The FDA had raised major concerns about the study design and the reliability of the data.

Investors didn’t find that out until July — when the FDA issued a rejection. The agency said the trial design was flawed and didn’t prove R-P1 actually worked. Replimune’s stock collapsed 77% in a single day.

Now, more shareholders are joining the lawsuit.

RxSight boasted about booming demand for its cataract surgery system.  But, in the end, the company took the scalpel to investors wallets.  After investors got blindsided by plummeting demand and a slashed revenue guidance, shareholders dumped their stock.  RxSight’s stock price crashed by almost 40%.  Now, investors are suing. 

RxSight manufacturers a surgical kit which it says helps people with cataracts. From late 2024 to early 2025, RxSight kept up a story of surging demand and great revenue.  In early 2025 it even issued an eye-popping revenue guidance.  But it was all smoke, no substance.

Investors learned the truth in July after the company admitted demand was crashing out.  The Company slashed its revenue guidance.  Furious investors dumped their shares, sending the stock into freefall. 

Now, more investors are joining the lawsuit.

Alto Neurosciences hyped up the promise of its new depression treatment.  But in the end, all that was left were broken promises and empty wallets.  When investors learned Alto’s new drug failed its clinical trials, despite months of executive spin, investors gave Alto a failing grade and dumped their shares.  The stock lost an eye-popping 70% in a day.  Now, investors are suing.

ALTO-100 was hyped as a novel treatment for clinical depression.  In February 2024, Alto Neurosciences released its IPO paperwork.  The IPO hyped-up the drug’s effectiveness and likelihood for getting the FDA’s okay.  For months, Alto execs kept touting the drug’s effectiveness and even said they had more trials in the pipeline.

But the spin spun out In October 2024.   Alto announced ALTO-100 failed its clinical trial and did no better than placebo.  Investors tossed out their shares like a box of broken test tubes and Alto’s stock went into freefall.

Now, more investors are joining the lawsuit.

Capricor said its new drug was on track for FDA approval — but the data didn’t deliver.
After months of hyping trial results and regulatory progress, Capricor’s application got rejected. The stock dropped 33%. Now, investors are suing.

Starting in late 2024, Capricor promoted its lead drug, deramiocel, as a breakthrough treatment for DMD-related cardiomyopathy. The company told investors its clinical trial results were strong — and that its application for FDA approval was on track. They even said the drug could get priority review.

But the lawsuit says Capricor left out critical facts. Internally, execs knew the study data didn’t meet the mark. They also knew about major manufacturing issues. But those execs kept insisting drug was likely to be approved.

In July 2025, the truth came out. The FDA formally rejected the drug, citing both weak evidence and production problems. Investors bailed — and the stock lost a third of its value in one day.

Now, more shareholders are joining the lawsuit.

Neogen told investors the 3M merger was cooking — but in reality everything was rotten.  For over a year, execs claimed the deal was “on track.” Then came a $461 million write-down, slashed guidance, and an 80% stock collapse when the merger synergies soured.  Now, investors are suing.

It started in early 2023. Neogen told investors the 3M Food Safety merger was going just fine. If there were hiccups, they’d fix them. And quarter after quarter, they said things were moving alone.

But the lawsuit says that was a recipe for disaster. Integration problems were stacking up, revenue was slipping, and execs allegedly knew a giant goodwill impairment was coming. They just didn’t say so.

Then, the whole thing crumbled. In January 2025, Neogen dropped the $461 million bombshell, admitted to internal control issues, and lowered its outlook. In April, they cut guidance again and announced the CEO was leaving. By June, margins tanked — again.

The stock didn’t just dip. It sank — 5% in January, 28% in April, 17% in June. Total damage? Nearly 80% gone.

Now, more shareholders are joining the lawsuit.

Torres v. Vestis Corporation, et al., Case No. 1:25-cv-04844 (S.D.N.Y.) is a securities fraud class action pending before the United States District Court for the Southern District of New York. The complaint, filed earlier in 2025, alleges that Vestis Corporation and certain of its executives violated federal securities laws by making false and misleading statements about the company’s operations and financial condition. According to the allegations, Vestis misrepresented key aspects of its business, inflating its stock price and causing losses to investors who purchased securities during the relevant period.

On August 25, 2025, the Honorable Gregory H. Woods issued an Order appointing the Board of Trustees of the Police Officers’ Retirement Plan and Trust Fund for the City of Miramar as Lead Plaintiff in the case. The Court also approved the Lead Plaintiff’s selection of Levi & Korsinsky, LLP as Lead Counsel.

A copy of the Court’s Order can be found here.

XPLR Infrastructure told investors its cash distributions were rock solid — but the whole model fell apart. After claiming its yieldco plan was secure through 2026, XPLR suddenly suspended all unitholder payouts and pivoted its business. The stock dropped 35%. Now, investors are suing.

In late 2023, XPLR said it had the money and the roadmap to keep growing distributions by 6% a year through at least 2026. Executives repeated that promise again and again.  They told investors they had “time,” and that XPLR wouldn’t need to raise more cash for at least a few years.  But, those execs knew better.

The lawsuit says XPLR was already struggling. Debt obligations were looming, liquidity was tight, and leadership had no way to keep up distributions without major issues. Just … investors weren’t told all this.

Then, in January 2025, the truth dropped. XPLR announced it was suspending all distributions and abandoning its yieldco model. Investors bailed. The stock plunged 35% in two days.

Now, more shareholders are joining the lawsuit.

iRobot said its Roomba comeback was ready to roll … but the only thing that got cleaned out was investors’ wallets. After big promises about revenue and recovery, iRobot posted weak sales, a massive loss, and ditched its 2025 forecast. The stock short-circuited and lost 27%. Now, investors are suing.

Back in January 2024, iRobot pitched its “Elevate” restructuring plan after the Amazon buyout fell apart. Executives said they’d streamline costs, reclaim market share, and break even on earnings. The company kept up that message throughout the year.

The lawsuit says none of it was working. The company hid fading demand, rising competition from Chinese brands, and serious operational snags. Meanwhile, execs told the public everything was squeaky clean.

Then, in March 2025, the truth came out. iRobot missed revenue expectations and reported a $71 million net loss. They pulled guidance entirely. Investors dumped the stock, and it crashed out.

Now, more shareholders are joining the lawsuit.

Petco left investors chasing their own tails after company execs barked about a pandemic-fueled boom and a health-focused future . . . that turned out to be an empty dish. When reality sank in, Petco’s stock dropped nearly 19%.  Now, investors are suing the company in a securities class action.

Beginning in early 2021, Petco’s top dogs painted a picture of sustainable growth. They cited “pet humanization,” strong premium food demand, and booming health services. Over the course of years, Petco’s earnings call and paperwork kept telling investors the company was doing great.  But, that was all bark, no bite. 

The health focus didn’t hold. The lawsuit says Petco downplayed fading pandemic trends, worsening supply chains, and shrinking demand. Sales slumped. The wellness story unraveled. By mid-2025, Petco dropped its full-year guidance.

In May, shares plunged 19% after Petco announced a jaw-dropping $47 million loss.

Now more investors are joining the lawsuit.

Hims said it could help people lose weight—but all that got lighter were investors’ wallets. The telehealth giant launched a weight-loss drug program in partnership with Novo Nordisk. But behind the scenes, Hims relied on a third-party compounding pharmacy that sourced ingredients from an unapproved Chinese supplier. When investors found out, Him stock plunged 34%.  Now, investors are suing. 

In April 2025, Hims bragged about a new collab with Novo Nordisk. Novo promised Hims a legitimate way to distribute Weygovy. This looked to be a huge win for Hims, with execs claiming the “legit” GLP-1 program could drive profits. 

But behind the scenes, the program included GLP-1s compounded using ingredients from a Chinese-based supplier not authorized by Novo. In June, Novo cut ties. Hims stock dropped 34% as investors realized the “legit” launch might not have been so clean after all.

Now, more investors are joining the lawsuit. 

Sarepta boasted about its breakthrough gene therapy. But when two patients died, trials were halted, the FDA came knocking, and the stock went into freefall. Now, investors are fighting back with a class-action lawsuit.

For two years, Sarepta executives sold a confident story about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy.  Execs called it a “watershed moment,” and bragged about strong demand.  They also emphasized ELEVIDYS was safe and effective. But according to the lawsuit, Sarepta had already missed early signs of danger.

The first warning came in March 2025, when Sarepta admitted a patient had died from acute liver failure after receiving ELEVIDYS. That same month, European regulators demanded a full safety review. Things got worse in June,  when a second ELEVIDYS patient died.  Sarepta suspended research. Just days later, the FDA launched an investigation.

Once investors heard that news, they quickly dumped their shares.  Sarepta’s stock plunged  27% after the first death, then another 42% in June after the second death.  It kept falling,  losing more than 60% of its value.

Now, more investors are joining the lawsuit.

PepGen Inc. promised investors a breakthrough cure for Duchenne muscular dystrophy.  But when the science wasn’t there, patients and shareholders were left heartbroken.  The stock crashed, and now investors are suing.

In twenty twenty-four, PepGen hyped its PGN-EDO51 drug, boasting it would deliver amazing results and a clear path to FDA approval.  But they hid dismal lab results, serious safety risks, and FDA scrutiny, leaving the stock price propped up on false promises.

The truth hit hard in late 2024 and 2025. Dismal trial data and major safety issues prompted FDA red flags.  PepGen had to ditch the program and investors dumped their shares. The stock plunged 32% in a day and kept tanking, costing hundreds of millions.

Now, more shareholders are joining the lawsuit.

Reckitt Benckiser promited its Enfamil formula would make both families and investors smile.  The bitter truth left everyone with tears.  The stock tanked, infants got harmed, and now investors are crying foul with a class-action lawsuit.

From 2021 to twenty 2024, Reckitt said its Enfamil formula was pediatricians’ top choice, totally safe, and backed by science.  This big claims boosted investor confidence.  But behind the scenes, executives were sitting on studies linking the formula to deadly intestinal disease in babies and mounting legal risks.

Then, in July 2024, executives got a taste of their own medicine.  Reports went public linking Enfamil to necrotizing entercolitis, a life-threatening condition.  Massive lawsuits followed, leading to a huge verdict against Reckitt.  Investors dumped their shares faster than spoiled milk, and Reckitt’s stock plummeted. 

Now, more investors are joining the lawsuit.

Meyer v. Weil et al, Case No. 24-C-23-003628, is a stockholder class action currently pending in the Circuit Court for Baltimore City, Maryland, before the Honorable Audrey J.S. Carrión. The lawsuit was filed by plaintiffs Robert G. Meyer and Thomas W. Miars on behalf of all owners of The Necessity Retail REIT, Inc. ("RTL") common stock as of September 12, 2023.

The complaint alleges that defendants Michael Weil, members of the RTL board, and AR Global Investments, LLCbreached their fiduciary duties to stockholders in connection with company governance and transactions, resulting in financial harm to investors.

On April 25, 2025, the parties agreed to a proposed settlement of $3.25 million in cash, which, if approved, will resolve all claims in the action. A Settlement Hearing has been scheduled for September 16, 2025 at 9:30 a.m., in person at the Circuit Court of Baltimore City, to determine, among other things, whether to grant final approval of the settlement, certify the class, approve the proposed plan of allocation, and award attorneys’ fees and expenses.

A copy of the Press Release can be found here: Necessity-Press Release

3D Systems thought it was printing money but in the end it was all just printer error.  After overly optimistic claims about revenue growth and its relationship with United Therapeutics, the company blindsided investors with a series of losses and news the United relationship hit a speed bump.  Investors sent their 3D shares through the shredder and the stock plunged over 26%.  Now, investors are suing.

3D Systems, a 3D printing pioneer, touted its “robust customer pipeline” and projected big revenue gains.  It also hyped its relationship with United Therapeutics, which seemed poised to bring in major cash for the 3D Systems’ healthcare sector.  But executives should have known better: in reality, the customer pipeline had slowed to a trickle and things weren’t great with United.

In March 2025, investors learned the truth.  3D Systems admitted a major shakeup to its United relationship would cost the company millions.  At the same time, the company missed revenue and sales projections.   Investors tossed out their shares and the stock plummeted. 

Now, more investors are joining the lawsuit. 

Vestis shareholders thought they were going to cleanup after the uniform rental company announced new growth plans.  But when investors learned the dirty truth and that executives knew those initiatives were bound to fail, it was investors who got taken to the cleaners.  The stock plunged 37% and now investors are suing.

Vestis is an Aramark spin-off which supplies uniforms and workplace products.  In 2024, company execs boasted about plans to improve sales, customer experiences, and customer retention.  They said these programs would lead to major revenue gains and plush margins.  But the lawsuit says behind-the-scenes, Vestis execs knew that was all bluster and that the company was plagued with massive problems.

The dirty laundry got aired in May 2025, when Vestis withdrew its guidance, an $8 million revenue drop, and a customer exodus.  Investors dumped their shares and the stock plummeted. 

Now more investors are joining the lawsuit.

Rocket Pharmaceuticals told investors its lead gene therapy was ready for liftoff; but in the end it failed to launch.  After failing to disclose a major study change that led to a patient’s death and an FDA clinical hold, Rocket’s stock crashed 37%. Now, investors are suing.

In early 2025, Rocket hyped its RPA-501 drug for Danon disease, promising strong safety data and a clear path to FDA approval.  Behind the scenes, the skies were cloudy.  Rocket secretly changed its trial protocol without telling investors. Then, in May, a patient who received updated treatment died from complications.

The FDA immediately grounded the entire trial. Investors didn’t wait. They dumped their shares, and Rocket’s stock collapsed.

Now, more shareholders are joining the lawsuit.

Red Cat said it was ready to soar, telling investors it could pump out “thousands” of drones per month.  But when investors learned that was a bunch of hot air, Red Cat’s stock took a crash landing.  Now, investors are suing.

In 2022, Red Cat execs told investors their Salt Lake City factor was ready for full-scale production.  They also bragged about a massive $260 million Army contract.  But there was some problems with all that bluster.  The factory wasn’t done and Red Cat couldn’t even churn out a hundred drones a month, let alone what the Army needed.

 Then, the real kicker: shortseller Kerrisdale Capital got its hands on the Army contract.  Kerrisdale found it the contract wasn’t worth anywhere close to what Red Cat led investors to believe.  Once investors learned this news, they dumped their shares and Red Cat’s stock crashed 27%.  Now, more investors are joining the lawsuit. 

DoubleVerify told investors it had cracked digital ads. But behind the buzzwords and Meta deals, it was just a bunch of zeros.  By early 2025, the stock cratered 70%.  Now, investors are suing to recover their losses.

According to the lawsuit, execs hyped their Activation Services as the future of ad targeting. They said growth was strong, rollout was smooth, and big revenue was on the way. The tools DoubleVerify’s big tools were really just a big flop and the Company knew it. Even worse, they allegedly charged advertisers for views from bots on data center servers.

Then, the slow burn.

February 2024.  guidance slashed. Stock down 21%.
May: another miss. Shares down 39%.
February 2025? Another 36% drop.
To add insult to injury,  Adalytics and the Wall Street Journal exposed the Bot view scam.

Now, more investors are joining the lawsuit.

Organon promised shareholders dividends were top priority. But after those dividends got slashed to pay down debt, shareholders dumped their Organon stock — and it was the stock price that got slashed next, dropping 27%. Now, enraged investors are fighting back with a class-action lawsuit against the Company.

In late 2024, Organon executives told investors the Company was in great shape. But after acquiring dermatology firm Dermavant, Organon found itself hemorrhaging cash — and fast. While execs publicly insisted the dividend was safe, internally it was another story. Those same executives were preparing to reroute dividend money to pay down the Dermavant debt… they just didn’t let investors in on that news right away.

Then came May 2025, when an earnings report left investors reeling. Organon announced it was slashing dividends and “resetting capital priorities.” Analysts panned the move. Investors raced for the exits, and Organon’s stock nosedived.

Now, more investors are joining the lawsuit.

It looked like Bitfarms had its crypto books in order. But behind the scenes, the numbers were breaking down.   Once the Company admitted to investors it needed to restate years of financial reporting because of major internal accounting weaknesses, investors knew it was time to press delete on Bitfarms.  Shareholders dumped their shares and Bitfarms stock lost 6%.  Now, investors are fighting back with a class action.

From March 2023 through most of 2024, Bitfarms presented itself as a company on solid footing. They said their internal controls were effective. Investors were told the company was handling its crypto transactions cleanly, with no red flags.

Behind the scenes, Bitfarms botched its accounting and seriously misclassified how it reported Bitcoin sales on its books.  This error puffed up key metrics of Bitfarms’ business performance.

But in December 2024, investors learned the truth behind the numbers. Bitfarms dropped a press release saying it would have to restate its financials for most of 2023 and 2024.

Within a day, investors ditched their shares and Bitfarms stock dropped.  Now, more investors are joining the lawsuit. 

Iovance Biotherapeutics told investors its cancer drug, Amtagvi, was set for mega revenue in 2025 — but all investors got was a mega letdown. After execs revealed Amtagvi’s rollout had been rolled over, investors pulled the plug, sending the stock into a 45% nosedive. Now, investors are suing.

Throughout 2024, Iovance executives said the Company was set for a massive 2025, projecting revenue in the high $400 millions. The reason for their optimism? Amtagvi, a supposed blockbuster cancer drug. But there was a catch: patients could only receive Amtagvi at specialized locations called Authorized Treatment Centers — or ATCs. Executives claimed the ATC rollout was moving quickly, and that more and more patients were starting treatment.

But all that bluster came crashing down in February 2025 when Iovance revealed dismal earnings and slashed its guidance by nearly 50%. The ATC rollout? Slow. Patient uptake? Slower. That so-called “blockbuster” rollout had barely gotten out of the gate.

Furious shareholders dumped their shares, and Iovance’s stock crashed 45%  in a single day. What was promised as a breakthrough was just plain broken. 

Now, more investors are joining the lawsuit.   

The securities fraud action Barnes v. Perpetua Resources Corp. et al., Case No. 1:25‑cv‑00160‑DKG, is pending before Magistrate Judge Debora K. Grasham in the U.S. District Court for the District of Idaho. The complaint, filed March 21, 2025, alleges that Perpetua Resources Corp. and certain of its officers violated federal securities laws by making misleading statements, causing losses to investors who purchased the company’s stock during the relevant period.

On June 16, 2025, Judge Grasham issued an Order appointing Carl Douglas Neale and David Wallentine as Co-Lead Plaintiffs. The Court also approved Levi & Korsinsky, LLP and Pomerantz LLP as Co‑Lead Counsel, and designated Mooney Wieland Warren LLP as Liaison Counsel.

A copy of the Court’s Order can be found here.

Cohen v. Quantum Computing Inc. et al, case no. 2:25-cv-01457, is a securities fraud case currently pending before Judge Jessica S. Allen in the U.S. District Court, District of New Jersey.  The lawsuit alleges Quantum and certain of its executives misled investors by overstating the capabilities of its quantum technologies and exaggerating the scope of its partnerships, including with NASA. The complaint also claims that Quantum failed to disclose related-party transactions.  Plaintiffs allege these misstatements artificially inflated Quantum's stock price, harming investors.  

On June 13, 2025, Judge Allen issued an Order appointing Jaeyeol Jung as lead plaintiff in the case.  Judge Allen also appointed Levi & Korsinsky, LLP as lead counsel in this matter.  

A copy of the Court's Order can be found here. 

Krispy Krispy promised investors they’d be rolling in the dough  -- but now it just finds itself in a sticky situation, leaving investors feeling glazed and confused.  Once shareholders learned their portfolios had gone stale, they tossed out their Krispy Kreme stock, sending it tumbling twenty-four percent.  Now, they’re suing for some sweet, sweet justice.

In 2024, Kreme Kreme told Wall Street it was baking up some major profits with a new McDonald’s partnership.  Executives bragged about strong demand, fat margins, and a national rollout that would light up the balance sheet.  Really, though, things weren’t fresh.

Demand at McDonalds was falling fast.  The partnership was a loser and Krispy Kreme execs were rethinking the partnership.  Publicly, though, they kept up the sugar-coated story. 

Then, in May 2025, the truth came out.  Kreme Kreme reported a 15% revenue drop, a $33 million loss, and admitted they were halting the McDonald’s expansion.

Investors dumped their shares faster than a cup of day-old coffee, sending Krispy Kreme shares crashing.  Now, more investors are joining the lawsuit.

Avis Budget told investors they had the roadmap to long term profits with its fleet rotation plan.  But after Avis admitted its plan hit a major bump, investors knew they’d just been taken for a ride.  Shareholders dumped their stock and Avis crashed nearly 7% in just a day.  Now, investors are taking legal action against the Company.

Avis Budget is the rental car giant behind brands like Avis, Budget, and Zipcar.  In 2024, they told shareholders their strategy to rotate older vehicles out of the rental fleet was the road to profits and boosted efficiency.  

But, according to the lawsuit, Avis misled investors by hiding risks and losses.  Executives said everything was fine, but really the fleet’s value was crashing fast. 

The truth came out in February, when Avis revealed a massive impairment charge and huge loss for Fourth Quarter 2024. 

Once investors heard this news dumped their shares and Avis’ stock plummeted.  Now, more investors are joining the lawsuit. 

Compass Holdings promised investors Lugano would shine like a diamond – only it was dull like a rock.  After Compass revealed it had major problems with its internal controls and Lugano’s accounting had lost its sparkle, investors found Compass’ shares lost their shine.  Shareholders raced for the exists and Compass’ stock price collapsed 62% in just a day.  Now investors are suing. 

Compass is a holding company for a number of brands, including Lugano Diamonds.  Throughout 2024, Compass executives repeatedly told investors and analysts that Lugano was the crown jewel in Compass’ portfolio, with Lugano putting up big earnings and massive margins.  Maybe. 

That story came crashing down in May 2025, after Compass admitted it had major problems with its financial statements and investors could no longer rely on those documents.  Worse?  There were serious irregularities in Lugano’s inventory and accounting.  That same day, Lugano’s CEO resigned and Compass announced a delay in its SEC filings.

Once investors hearing this news, they knew Compass had lost its way and dumped their shares.  Now, more investors are joining the lawsuit. 

It’s a breakup story gone sour. Digimarc told investors they were gonna fall hard – for big contracts, big earnings, and big momentum. But when Digimarc’s largest trading partner said it was done, Digimarc didn’t have the heart to break the news -- not right away. And when investors finally found out? They walked too, and the only thing falling was Digimarc’s stock price.  Now, investors are suing.

From late 2023 to early 2024 , Digimarc boasted about big revenue gains and strong “momentum.” They told investors demand was strong, contract wins were rolling in, and the company's transformation was underway.

What they didn’t say was that their most important trading partner had already pulled the plug. Instead of coming clean, Digimarc just kept up the act. Then came February 2025, when the truth came out and Digimarc slashed its guidance.

Jilted investors dumped their Digimarc shares, sending its stock price plunging.  Now, more investors are joining the lawsuit.

Napco Security Technologies investors are sounding the alarm after the company’s claims about big margins turned about to be a ton of smoke.  When investors learned the truth about Napco’s empty promises, the Company’s stock fizzled out.  Now investors are fighting back with lawsuit to hold the company accountable.

Throughout 2024, Napco executives painted a rosy picture of rising demand and growth, telling investors they were “well on our way” to hitting a 45% margin by 2026. But beneath the surface, Napco’s hardware division was losing traction, and its margin forecasts were built more on wishful thinking than reliable data.

By early 2026, the truth came out: Napco’s hardware sales had dropped sharply: down 25% in Q-2, and margins shrank as key distributors slashed orders. The company admitted it could no longer confirm whether its fiscal 2026 goals were achievable.  Once investors heard this news, they raced for the exits and Napco’s share price tanked.  Now, more investors are joining the lawsuit.   

Open Lending may have been in the business of protecting lenders, but now its shareholders need some protection of their own. For years, the company hyped the strength of its pricing models . . . but those models turned out to be subprime, causing things to vault out of control fast. LRPO shares nosedived more than 50%, and now investors are taking action with a class-action against the company.

The lawsuit alleges Open Lending misled investors about the reliability of its loan pricing models for near-prime borrowers. According to the complaint, loans from 2021-22 were already deteriorating as used car values dropped. Even worse, loans from 2023-24 performed terribly, tied to high-risk borrower pools. Despite all the warning signs, Open Lending insisted everything was fine.

In March 2025, investors learned the truth after Open revealed a massive revenue revision, a gigantic net loss, and a mass executive exodus. Investors fled, too, and shares plummeted 57% in a single day. Now more investors are joining the lawsuit.

Ibotta, Inc. may have promised cash back to consumers, but now its investors are the ones wanting some cash back. The tech firm behind digital promotions went public in April 2024 at $88 per share.  But after troubling revelations just months later, its stock price nosedived.  Now, investors are taking action with a class-action lawsuit against the company.

The case is about what Ibotta didn’t say. According to the lawsuit, Ibotta’s IPO paperwork forgot to mention its major partnership with Kroger was an at-will contract, meaning Kroger could walk away at any time, no strings attached.   

Investors learned the truth August 2024, when Ibotta filed its quarterly report with the SEC, conspicuously omitting any mention of Kroger. That silence said everything, signaling to investors that the Kroger partnership was probably done.  

Investors responded swiftly, with Ibotta’s way down from its IPO high. Now more shareholders are joining the lawsuit.

Civitas Resources promised energy for the future — but now, it’s shareholders who are feeling burned out. After touting strong production in Colorado and Texas, the company’s stock dropped more than 18% overnight, falling to just over $40 per share. The reason? A financial report that struck a different tone — and now, investors are taking action with a class-action lawsuit against Civitas.

The lawsuit claims that throughout 2024, Civitas painted an overly optimistic picture of its oil and gas assets. While executives highlighted production growth, efficiency gains, and a healthy balance sheet, the complaint says they failed to disclose that oil output in the DJ Basin had already peaked. On top of that, the company was allegedly slowing down new well development — and would need to take on debt and sell off assets just to keep pace. Also left out of the conversation? A 10% workforce reduction.

When the truth emerged in February 2025, investors got a dose of financial whiplash. Revenue and earnings missed expectations, interest expenses soared past $450 million, and net income was cut in half compared to the prior year. Civitas’s stock price plunged by more than $8 per share, and the damage was done.

Now more investors are joining the lawsuit to hold Civitas accountable.

 Canopy Growth gave investors a major high when it said it was rolling in the green and margins were expanding.  So, it was a big buzz kill when investors discovered not only were Canopy’s margins down, but its shipping costs were out of control, too.  Disappointed investors burned their Canopy shares, sending the stock’s price crashing 27%.  Now some of those investors are taking legal action.

Canopy Growth is a cannabis grower and distributer.  Throughout 2024, it boasted improved margins, especially for it's vape brand.  Company executives also claimed improved manufacturing efficiency for its pre-rolled joints helped Canopy’s bottom line. 

But, lawsuit says that was all just a trip. 

In February 2025, Canopy issued a press release stating its margins were down.  Executives blamed the roll-out of its Claybourne pre-roll joints, which costed more than expected, and increased shipping costs related to it's vape brands. 

Upset investors sold off their shares, sending Canopy stock crashing.  More investors are now joining the lawsuit.

Solaris Energy left investors in the dark when it bought out a company with no employees, no turbines, and no track record.  When investors saw the light, they shut off their Solaris shares, sending the stock’s price crashing almost seventeen percent.  Now, some investors have filed a class action against the Company. 

Solaris Energy provides equipment in the oil and gas industry.  In July 2024, it announced the buy-out of MER.  Solaris finalized the MER buy-out in September and boasted about the major value MER provided to Solaris. 

But, the lawsuit says the only thing MER brought Solaris was a ton of debt.

In March 2025, Morpheus Research published a report showing MER has no employees, no turbines, and no track record in the energy industry.  In fact, the report says MER’s CEO is a convicted conman.  Morpheus also alleged Solaris was using dodgy accounting methods to fraudulently boost its assets. 

When investors got wind of this news, they dumped their shares and Solaris’ stock price tumbled.  Now more investors are joining the lawsuit.